Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Monte Rosa Therapeutics (GLUE) Receivables - Other (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Receivables - Other data on record, last reported at $5.0 million in Q3 2025.

  • For Q3 2025, Receivables - Other rose 734.45% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, up 734.45%, while the annual FY2024 figure was $173000.0, 65.74% down from the prior year.
  • Receivables - Other reached $5.0 million in Q3 2025 per GLUE's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $5.0 million in Q3 2025 and bottomed at $173000.0 in Q4 2024.
  • Average Receivables - Other over 3 years is $1.4 million, with a median of $842000.0 recorded in 2024.
  • Peak YoY movement for Receivables - Other: tumbled 72.3% in 2024, then soared 734.45% in 2025.
  • A 3-year view of Receivables - Other shows it stood at $505000.0 in 2023, then plummeted by 65.74% to $173000.0 in 2024, then skyrocketed by 2769.94% to $5.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $5.0 million in Q3 2025, $2.4 million in Q2 2025, and $1.4 million in Q1 2025.